Riociguat denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Riociguat as Non-Formulary

BCBS formularies — the lists of covered drugs — are designed around cost management and therapeutic substitution, not around what is best for any individual patient. When riociguat is placed on a non-covered or high-restriction tier, BCBS is applying a blanket rule that may not account for why riociguat is specifically appropriate for your pulmonary hypertension. Non-formulary status does not mean the drug is ineffective or inappropriate; it means the plan did not negotiate favorable terms for it or prefers alternatives for administrative reasons.

## Why This Denial Is Appealable

All plans that cover pulmonary hypertension treatment must consider formulary exceptions when no covered formulary alternative is clinically appropriate for a specific patient. Riociguat's distinct mechanism and approved indications mean it is not simply interchangeable with every other pulmonary hypertension agent. Under federal law: - ACA §2719 / ERISA §503 require a full-and-fair internal appeal with written clinical reasoning. - External review by an independent review organization is available after internal denial; the window is generally up to approximately four months from the denial notice — verify the exact deadline on your Explanation of Benefits. - Expedited review is available when delay would seriously jeopardize health.

## Your Appeal Process and Timeline

1. Request BCBS's formulary exception criteria and identify the specific formulary alternatives BCBS would cover for your diagnosis. 2. For each formulary alternative, document the clinical reason it is not appropriate for you: prior failure, intolerance, contraindication, or a distinct clinical indication that only riociguat covers (for example, CTEPH, which has a limited drug treatment landscape). 3. File the internal appeal — including a formulary exception request — with complete documentation. 4. If denied, request external review without delay.

## Documentation to Gather

• Diagnosis confirmation: records establishing your specific pulmonary hypertension subtype (PAH vs. CTEPH), as the approved indications for different drugs vary by subtype.
• Trial-and-failure records: for each formulary alternative BCBS identified, chart notes or prescriber letters documenting the outcome of prior use or the clinical reason the drug cannot be used.
• Prescriber letter: specifically addressing why riociguat is the appropriate drug for your subtype and clinical profile, and why the formulary alternatives are not equivalent options — referencing the applicable ACC/AHA or ERS/ESC guideline organization and the FDA-approved prescribing information for riociguat.
• FDA prescribing information: showing riociguat's specific approved indications and the populations it is designed for.

## Criteria-Mapping Structure

Review BCBS's formulary exception policy and place each requirement next to the supporting clinical evidence. Pay particular attention to diagnosis subtype — a CTEPH patient may have a straightforward case for riociguat that a generic non-formulary denial completely overlooks. Specificity in your documentation is the single most important factor in formulary exception appeals.